Invesco Ltd. Invests $4.98 Million in Kestra Medical Technologies, Ltd. $KMTS

Key Points

• Invesco Ltd. acquired 200,000 shares of Kestra Medical Technologies, valued at approximately $4.98 million, during the first quarter.
• Several other large investors also increased their stakes in Kestra Medical Technologies, with Brown Advisory Inc. leading with a new investment of $13.72 million.
• Wells Fargo & Company lowered their price target on Kestra Medical Technologies from $28.00 to $27.00, maintaining an "overweight" rating, while the stock currently holds an average rating of "Moderate Buy."

Invesco Ltd. bought a new position in shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 200,000 shares of the company's stock, valued at approximately $4,984,000. Invesco Ltd. owned approximately 0.39% of Kestra Medical Technologies as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of KMTS. Caas Capital Management LP bought a new position in Kestra Medical Technologies in the first quarter valued at about $1,470,000. Jennison Associates LLC acquired a new stake in Kestra Medical Technologies during the first quarter worth approximately $1,869,000. TD Asset Management Inc acquired a new stake in Kestra Medical Technologies during the first quarter worth approximately $2,306,000. Federated Hermes Inc. bought a new stake in shares of Kestra Medical Technologies during the first quarter valued at approximately $9,968,000. Finally, Brown Advisory Inc. bought a new stake in shares of Kestra Medical Technologies during the first quarter valued at approximately $13,716,000.

Kestra Medical Technologies Trading Down 0.1%

KMTS stock traded down $0.02 during trading on Tuesday, hitting $16.12. 636,525 shares of the company traded hands, compared to its average volume of 166,180. Kestra Medical Technologies, Ltd. has a 1 year low of $13.25 and a 1 year high of $26.15. The stock has a 50-day moving average of $16.21. The company has a debt-to-equity ratio of 0.20, a current ratio of 6.72 and a quick ratio of 6.72.

Analyst Ratings Changes

Separately, Wells Fargo & Company cut their price objective on Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating on the stock in a research report on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, Kestra Medical Technologies currently has a consensus rating of "Moderate Buy" and an average target price of $27.33.

Kestra Medical Technologies Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.